Last reviewed · How we verify
Fenoldopam mesilate
Fenoldopam mesilate is a selective dopamine-1 (DA1) receptor agonist that causes vasodilation and increases renal blood flow.
Fenoldopam mesilate is a selective dopamine-1 (DA1) receptor agonist that causes vasodilation and increases renal blood flow. Used for Acute hypertension in hospitalized patients, Hypertensive crisis.
At a glance
| Generic name | Fenoldopam mesilate |
|---|---|
| Also known as | Corlopam |
| Sponsor | IRCCS Policlinico S. Donato |
| Drug class | Dopamine-1 receptor agonist |
| Target | Dopamine-1 (DA1) receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Fenoldopam selectively binds to dopamine-1 receptors on vascular smooth muscle and renal vasculature, leading to peripheral and renal vasodilation. This results in decreased systemic vascular resistance, lowered blood pressure, and improved renal perfusion. It is used primarily for acute hypertension management in hospital settings.
Approved indications
- Acute hypertension in hospitalized patients
- Hypertensive crisis
Common side effects
- Tachycardia
- Headache
- Dizziness
- Nausea
- Flushing
- Hypotension
Key clinical trials
- Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury (PHASE4)
- Vasodilators and Anti-Oxidant Therapy in Early ATN (PHASE2, PHASE3)
- Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fenoldopam mesilate CI brief — competitive landscape report
- Fenoldopam mesilate updates RSS · CI watch RSS
- IRCCS Policlinico S. Donato portfolio CI